Apr 5 2024Dana-Farber Cancer Institute In this study, tumors were reduced in six out of 16 patients treated with the combination, including one case in which the cancer disappeared.
Rebecca Porter, MD, PhD, principal investigator, medical oncologist in the Gynecological Oncology Program of Dana-Farber's Susan F. Smith Center for Women's Cancers About 30% of patients with serous endometrial cancer have tumors that express FRα, the target of mirvetuximab soravtansine, an antibody-drug conjugate . ADCs work by pairing a potent anti-cancer drug with an antibody that directs the drug to cells that express a certain marker, such as FRα. In earlier work, it was shown that serous endometrial cancers likely have the highest expression of FRα, which provided the rationale to focus on this population in the current study.
Porter and colleagues designed the two-stage trial as a single arm study in which all patients receive the same treatment. The first stage recruited 16 patients with recurrent or persistent FRα positive, MSS/pMMR serous endometrial cancer who were previously treated with one to four lines of therapy. The second stage would proceed to enroll additional patients if there were at least two objective responses or two cases of six-month, progression-free survival in the first stage.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Scientists using novel hydrogel to create 'lollipops' for mouth cancer diagnosticResearchers from the University of Birmingham, U.K., are creating a new 'lollipop' diagnostic for mouth cancer using a novel smart hydrogel.
Source: medical_xpress - 🏆 101. / 51 Read more »
Novel oral hormone therapy shows promising results for prostate cancer treatment with radiation therapyA study led by Daniel Spratt, M.D., Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer. This work is published in JAMA Oncology.
Source: medical_xpress - 🏆 101. / 51 Read more »
Novel theranostic tool allows for noninvasive identification and treatment of ovarian cancerA new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of the Journal of Nuclear Medicine. Combining the highly specific huAR9.
Source: medical_xpress - 🏆 101. / 51 Read more »
Novel ADC and immunotherapy combo shows promise in endometrial cancer subtypeIn a small, investigator-initiated Phase II study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.
Source: medical_xpress - 🏆 101. / 51 Read more »
Breast Cancer Now funds researchers to investigate targeted radiotherapy for metastatic breast cancer in the brainResearchers are trialing a new type of targeted radiotherapy to treat secondary breast cancer tumors in the brain, thanks to new funding from Breast Cancer Now.
Source: NewsMedical - 🏆 19. / 71 Read more »
Lung cancer tissue specimens for accelerating cancer researchBioIVT offers immediate shipment of FFPE and Fresh Frozen lung cancer tissue specimens for cancer research and custom research protocols.
Source: NewsMedical - 🏆 19. / 71 Read more »